Confronto

Buserelin vs. Icatibant

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

57982-77-1

138614-30-9

Peso molecolare

1239.42 g/mol

1304.52 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Buserelin	Icatibant
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Buserelin and Icatibant?: Buserelin is classified as "Ricerca (altro)", while Icatibant is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Icatibant?: The highest available evidence level is "RCT sull'uomo" for Buserelin and "RCT sull'uomo" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Icatibant in Germany and the United States?: Germania: Buserelin — Su prescrizione, Icatibant — Su prescrizione. Stati Uniti: Buserelin — Non approvato, Icatibant — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Icatibant

Germania

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Buserelin and Icatibant?

Buserelin is classified as "Ricerca (altro)", while Icatibant is classified as "Ricerca (altro)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Icatibant?

The highest available evidence level is "RCT sull'uomo" for Buserelin and "RCT sull'uomo" for Icatibant. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Icatibant in Germany and the United States?

Germania: Buserelin — Su prescrizione, Icatibant — Su prescrizione. Stati Uniti: Buserelin — Non approvato, Icatibant — Su prescrizione. These are factual summaries with source and review date on the individual pages.